Bartronics India makes strategic investment of up to Rs 50 Cr in Huwel Life Sciences

image credit- shutterstock

Hyderabad-based Bartronics India Limited (BIL), a listed technology and services company, has announced a strategic investment of up to Rs 50 crore in Huwel Life Sciences, a molecular diagnostics startup, also based in Hyderabad.

Under this Memorandum of Understanding (MoU), BIL will acquire a 15% equity stake in Huwel, bringing together its scaling expertise with Huwel’s innovation capabilities to accelerate India’s health goals. BIL also holds an option to increase its equity stake by an additional 15%”. 

Huwel Life Sciences has developed more than 100 validated diagnostic products across tuberculosis (TB), infectious diseases, antimicrobial resistance, viral threats, genetic disorders, and cancer. Huwel has secured grants from the Bill & Melinda Gates Foundation, received orders from the World Health Organization, and continues to build global credibility through partnerships and product adoption worldwide.

The flagship product of Huwel’s portfolio is its breakthrough low-cost TB solution. Huwel has developed the Quantiplus® TB Fast Detection Kit. QuantiPlus is approved by ICMR and was launched by the Union Health Minister. It is the only open-system, affordable RT-PCR solution for TB confirmatory testing in India. 

Under this strategic partnership with Huwel, BIL will assume end-to-end responsibility for driving market growth, delivering technology support, managing digital outreach, and developing customised applications, portals, and digital platforms. BIL will take the lead in identifying prospective opportunities, initiating engagements, negotiating commercial terms, and securing government, institutional, and international orders — while ensuring that all activities are structured to safeguard and enhance the long-term value interests of both partners.

This partnership guarantees assured revenue for BIL. A designated subsidiary will manage a major share of business execution, which creates predictable and recurring income streams. Beyond revenue, BIL and Huwel will drive R&D, launch new products, and expand internationally.